Impact of reducing complement inhibitor binding on the immunogenicity of native neisseria meningitidis outer membrane vesicles

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Daniels Treffandier, Helene ^a   Nie, Karlijn De ^a   Marsay, Leanne ^a   Dold, Christina ^a   Sadarangani, Manish ^a   Reyes Sandoval, Arturo ^b   Langford, Paul R ^c   Wyllie, David ^b   Hill, Fergal ^d   Pollard, Andrew J ^a   Rollier, Christine S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Imaxio SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; NEISSERIAL SURFACE PROTEIN A; UNCLASSIFIED DRUG; COMPLEMENT FACTOR H, HUMAN; COMPLEMENT INHIBITOR; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

AGE RELATED MACULAR DEGENERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; GENE DELETION; IMMUNOGENICITY; LPXL1 GENE; NEISSERIA MENINGITIDIS; NONHUMAN; NSPA GENE; PROTEIN PURIFICATION; RAT; ANIMAL; ANTIBODY PRODUCTION; C57BL MOUSE; FEMALE; HUMAN; IMMUNIZATION; IMMUNOLOGY; MENINGITIS, MENINGOCOCCAL; MOUSE;

ANIMALS; ANTIBODY FORMATION; BACTERIAL OUTER MEMBRANE PROTEINS; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; FEMALE; HUMANS; IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS;

EID: 84960533406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148840     Document Type: Article

References (40)

1. Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child. 2012;97(11):993-8. Epub 2012/09/18. doi: 10.1136/archdischild-2012-302036 PMID: 22984187; PubMed Central PMCID: PMC3512348.
2. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30 Suppl 2:B26-36. Epub 2011/12/20. doi: 10.1016/j.vaccine.2011.12.032 PMID: 22178525.
3. Finne J, Leinonen M, Makela P H. Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis. Lancet. 1983;2:355-7. PMID: 6135869
4. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis. 2010;10(2):112-24. Epub 2010/02/02. doi: 10.1016/S1473-3099 (09) 70324-X PMID: 20113980.
5. Sanders H, Feavers IM. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines. 2011;10(3):323-34. doi: 10.1586/erv. 11.10 PMID: 21434800.
6. Rollier CS, Dold C, Marsay L, Sadarangani M, Pollard AJ. The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy. Expert opinion on biological therapy. 2015;15(1):131-42. Epub 2014/12/09. doi: 10.1517/14712598.2015.983897 PMID: 25482879.
7. Van Der Ley P, Van Den Dobbelsteen G. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin. 2011;7(8):886-90. Epub 2011/07/26. doi: 10.4161/hv. 7.8.16086 PMID: 21785281.
8. Griffiths NJ, Hill DJ, Borodina E, Sessions RB, Devos NI, Feron CM, et al. Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance. Mol Microbiol. 2011;82(5):1129-49. doi: 10.1111/j.1365-2958.2011.07876.x PMID: 22050461.
9. Jarva H, Ram S, Vogel U, Blom AM, Meri S. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol. 2005;174(10):6299-307. PMID: 15879129.
10. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010;6(7):e1001027. Epub 2010/08/06. doi: 10.1371/journal.ppat. 1001027 PMID: 20686663; PubMed Central PMCID: PMC2912398.
11. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458(7240):890-3. Epub 2009/02/20. doi: nature07769 [pii] doi: 10.1038/nature07769 PMID: 19225461; PubMed Central PMCID: PMC2670278.
12. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell research. 2010;20(1):34-50. doi: 10.1038/cr.2009.139 PMID: 20010915.
13. Granoff DM, Ram S, Beernink PT. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? Clin Vaccine Immunol. 2013;20(8):1099-107. Epub 2013/06/07. doi: 10.1128/CVI.00260-13 PMID: 23740919; PubMed Central PMCID: PMC3754512.
14. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501-10. Epub 2006/06/21. doi: 177/1/501 [pii]. PMID: 16785547; PubMed Central PMCID: PMC2248442.
15. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011;186(6):3606-14. doi: 10.4049/jimmunol.1003470 PMID: 21325619; PubMed Central PMCID: PMC3098282.
16. Frandoloso R, Martinez-Martinez S, Calmettes C, Fegan J, Costa E, Curran D, et al. Nonbinding sitedirected mutants of transferrin binding protein B exhibit enhanced immunogenicity and protective capabilities. Infect Immun. 2015;83(3):1030-8. doi: 10.1128/IAI.02572-14 PMID: 25547790; PubMed Central PMCID: PMC4333475.
17. Zariri A, Van Dijken H, Hamstra HJ, Van Der Flier M, Vidarsson G, Van Putten JP, et al. Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles. Vaccine. 2013;31(47):5585-93. doi: 10.1016/j.vaccine.2013.07.069 PMID: 23933369.
18. Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT. Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine. J Infect Dis. 2015. doi: 10.1093/infdis/jiv081 PMID: 25676468.
19. Fakhouri F, De Jorge EG, Brune F, Azam P, Cook HT, Pickering MC. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney international. 2010;78(3):279-86. doi: 10.1038/ki.2010.132 PMID: 20445496; PubMed Central PMCID: PMC2906702.
20. Sambrook JR, DW. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor NY 2001.
21. Van Dam V, Bos MP. Generating knock-out and complementation strains of Neisseria meningitidis. Methods Mol Biol. 2012;799:55-72. doi: 10.1007/978-1-61779-346-2-4 PMID: 21993639.
22. Nagaputra JC, Rollier CS, Sadarangani M, Hoe JC, Mehta OH, Norheim G, et al. Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens. Clin Vaccine Immunol. 2014;21(2):234-42. Epub 2013/12/20. doi: 10.1128/CVI.00561-13 PMID: 24351756; PubMed Central PMCID: PMC3910940.
23. Bosse JT, Durham AL, Rycroft AN, Kroll JS, Langford PR. New plasmid tools for genetic analysis of Actinobacillus pleuropneumoniae and other pasteurellaceae. Applied and environmental microbiology. 2009;75(19):6124-31. doi: 10.1128/AEM.00809-09 PMID: 19666733; PubMed Central PMCID: PMC2753053.
24. Van Der Voort ER, Van Der Ley P, Van Der Biezen J, George S, Tunnela O, Van Dijken H, et al. Specificity of human bactericidal antibodies against PorA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun. 1996;64(7):2745-51. PMID: 8698504; PubMed Central PMCID: PMC174135.
25. Van De Waterbeemd B, Streefland M, Van Keulen L, Van Den Ijssel J, De Haan A, Eppink MH, et al. Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine. 2012;30(24):3683-90. doi: 10.1016/j.vaccine.2012.03.028 PMID: 22464965.
26. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009;77(2):764-9. doi: 10.1128/IAI.01191-08 PMID: 19047406; PubMed Central PMCID: PMC2632036.
27. Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12(8):970-6. Epub 2005/08/09. doi: 10.1128/CDLI.12.8.970-976.2005 PMID: 16085915; PubMed Central PMCID: PMC1182195.
28. Van Der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun. 1992;60(8):3156-61. PMID: 1639486; PubMed Central PMCID: PMC257296.
29. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197(6):789-99. Epub 2003/03/19. doi: 10.1084/jem.20021911 PMID: 12642606; PubMed Central PMCID: PMC2193853.
30. Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010;28(9):2122-9. Epub 2010/01/02. doi: 10.1016/j.vaccine.2009.12.027 PMID: 20044056; PubMed Central PMCID: PMC2830318.
31. McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiology and molecular biology reviews: MMBR. 2013;77(2):234-52. doi: 10.1128/MMBR.00056-12 PMID: 23699256; PubMed Central PMCID: PMC3668674.
32. Lewis LA, Carter M, Ram S. The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol. 2012;188(10):5063-72. doi: 10.4049/jimmunol.1103748 PMID: 22504643; PubMed Central PMCID: PMC3345070.
33. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio. 2013;4(5):e00339-13. doi: 10.1128/mBio.00339-13 PMID: 24129254; PubMed Central PMCID: PMC3812710.
34. Giuntini S, Pajon R, Ram S, Granoff DM. Binding of Complement Factor H to PorB3 and NspA Enhances Resistance of Neisseria meningitidis to Anti-Factor H Binding Protein Bactericidal Activity. Infect Immun. 2015;83(4):1536-45. doi: 10.1128/IAI.02984-14 PMID: 25644002.
35. Van Der Veen S, Johnson S, Jongerius I, Malik T, Genovese A, Santini L, et al. Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun. 2014;82(3):1157-63. Epub 2014/01/01. doi: 10.1128/IAI.01183-13 PMID: 24379280; PubMed Central PMCID: PMC3958001.
36. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 2012;8(5):e1002688. Epub 2012/05/17. doi: 10.1371/journal. ppat.1002688 PMID: 22589720; PubMed Central PMCID: PMC3349754.
37. Ufret-Vincenty RL, Aredo B, Liu X, McMahon A, Chen PW, Sun H, et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Investigative ophthalmology & visual science. 2010;51(11):5878-87. doi: 10.1167/iovs.09-4457 PMID: 20538999.
38. Tappero JW, et al. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines. A randomised clinical trial in Chile. J Am Med Assoc 1999;281:1520-7.
39. Lai Z, Schreiber JR. Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM (1) (9) (7) conjugate vaccine. Clin Vaccine Immunol. 2011;18(5):724-9. Epub 2011/04/01. doi: 10.1128/cvi.00053-11 PMID: 21450979; PubMed Central PMCID: PMCPmc3122513.
40. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A. 2006;103(48):18243-8. doi: 10.1073/pnas.0608545103 PMID: 17110440; PubMed Central PMCID: PMC1636993.